| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2113228 | Cancer Letters | 2012 | 10 Pages |
Abstract
We generated a fusion protein Bax345/BLyS containing the truncated form of Bax (Bax345) at the N-terminus followed by a 218 linker to the B lymphocyte stimulator (BLyS). Bax345/BLyS was cytotoxic to a panel of diffuse large B cell lymphoma and mantle cell lymphoma lines expressing the BLyS receptors. Specific delivery of Bax345/BLyS to malignant B cells drove cells into apoptosis by mitochondrial dysfunction and treatment of cells with Bax345/BLyS induced down-regulation of Mcl-1, X-IAP, and survivin. Bax345/BLyS represents a new class of targeted therapeutic agents with a unique mechanism of action and may have therapeutic potential for malignant B cells.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mi-Ae Lyu, Lawrence H. Cheung, Walter N. Hittelman, Yuying Liu, John W. Marks, Min-Jeong Cho, Michael G. Rosenblum,